Previous Close | 14.47 |
Open | 14.50 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's Range | 13.87 - 14.64 |
52 Week Range | 7.81 - 16.91 |
Volume | |
Avg. Volume | 897,427 |
Market Cap | 1.317B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.04 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for FGEN
Every investor in FibroGen, Inc. ( NASDAQ:FGEN ) should be aware of the most powerful shareholder groups. Insiders...
FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021Continued significant roxadustat volume growth in China SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the company’s recent developments. “We continue making excellent progress with pamrevlumab across al